Sexually Transmitted Diseases (STD) Testing Market Size, Share & COVID-19 Impact Analysis, By Product Type (Instruments and Reagents & Kits), By Application (Chlamydia, Syphilis, Genital Herpes, Gonorrhea, Human Immunodeficiency Virus, Human Papillomavirus, and Others), By Setting (Laboratory Testing and Point-of-Care), By End User (Hospital & Clinics, Diagnostic Centers, and Others), and Regional Forecast, 2026-2034

  ATTRIBUTE

  DETAILS

Study Period

2021-2034

Base Year

2025

Forecast Period

2026-2034

Historical Period

2021-2024

Growth Rate

CAGR of 9.10% from 2026 to 2034

Unit

Value (USD billion)

Segmentation

By Product Type, Application, Setting, End User, and Region

By Product Type

• Instruments
• Reagents & Kits

By Application

• Chlamydia
• Syphilis
• Genital Herpes
• Gonorrhea
• Human Immunodeficiency Virus
• Human Papillomavirus
• Others

By Setting

• Laboratory Testing
• Point-of-Care

By End User

• Hospital & Clinics
• Diagnostic Centers
• Others

By Region

• North America (By Product Type, By Application, By Setting, By End User, By Country)
  • U.S.
  • Canada
• Europe (By Product Type, By Application, By Setting, By End User, By Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Product Type, By Application, By Setting, By End User, By Country/Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product Type, By Application, By Setting, By End User, By Country/ Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product Type, By Application, By Setting, By End User, By Country/Sub-Region)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa